Optimizing transitional pharmacotherapeutic care
Period 2022-2026
Polypharmacy (the use of > 5 medications daily) poses an ongoing healthcare challenge, as it is associated with negative outcomes such as adverse drug events, lower quality of life and mortality. These risks are especially elevated for the frail and old, leading to high numbers of drug related admissions (DRAs) and unplanned emergency department visits. Unfortunately, up till now, despite multiple efforts to decrease drug related harm with different intervention strategies, the number of drug related admissions has not decreased. In the LIMONCELLO-study, we will study an optimised transitional pharmacotherapeutic care intervention, with extra focus on multidisciplinary and patient-centered care, in a patient population that has an elevated risk for drug related hospital admissions due to risk factors such as old age and multimorbidity. We hypothesise that transitional multidisciplinary pharmacotherapeutic care (TMPC) is superior in preventing drug related readmissions (DRreAs) compared to usual care.
More information can be found here.
PhD-student: Eline Engelen,
e.m.c.engelen@amsterdamumc.nl
Promotor: Prof. dr. M.A. van Agtmael
Co-promotors: Dr. W. Knol & S. Wuyts
Polypharmacy (the use of > 5 medications daily) poses an ongoing healthcare challenge, as it is associated with negative outcomes such as adverse drug events, lower quality of life and mortality. These risks are especially elevated for the frail and old, leading to high numbers of drug related admissions (DRAs) and unplanned emergency department visits. Unfortunately, up till now, despite multiple efforts to decrease drug related harm with different intervention strategies, the number of drug related admissions has not decreased. In the LIMONCELLO-study, we will study an optimised transitional pharmacotherapeutic care intervention, with extra focus on multidisciplinary and patient-centered care, in a patient population that has an elevated risk for drug related hospital admissions due to risk factors such as old age and multimorbidity. We hypothesise that transitional multidisciplinary pharmacotherapeutic care (TMPC) is superior in preventing drug related readmissions (DRreAs) compared to usual care.
More information can be found here.
PhD-student: Eline Engelen,
e.m.c.engelen@amsterdamumc.nl
Promotor: Prof. dr. M.A. van Agtmael
Co-promotors: Dr. W. Knol & S. Wuyts